278 related articles for article (PubMed ID: 27429002)
1. Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling.
Pećina-Šlaus N; Kafka A; Lechpammer M
Cancers (Basel); 2016 Jul; 8(7):. PubMed ID: 27429002
[TBL] [Abstract][Full Text] [Related]
2. Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.
Pećina-Šlaus N; Kafka A; Vladušić T; Tomas D; Logara M; Skoko J; Hrašćan R
Int J Exp Pathol; 2016 Apr; 97(2):159-69. PubMed ID: 27292269
[TBL] [Abstract][Full Text] [Related]
3. Pathological classification and molecular genetics of meningiomas.
Mawrin C; Perry A
J Neurooncol; 2010 Sep; 99(3):379-91. PubMed ID: 20809251
[TBL] [Abstract][Full Text] [Related]
4. AXIN1 Expression and Localization in Meningiomas and Association to Changes of APC and E-cadherin.
Pećina-Šlaus N; Kafka A; Vladušić T; Pećina HI; Hrašćan R
Anticancer Res; 2016 Sep; 36(9):4583-94. PubMed ID: 27630299
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.
Wallesch M; Pachow D; Blücher C; Firsching R; Warnke JP; Braunsdorf WEK; Kirches E; Mawrin C
J Neurol Sci; 2017 Sep; 380():112-121. PubMed ID: 28870549
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
[TBL] [Abstract][Full Text] [Related]
7. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
[TBL] [Abstract][Full Text] [Related]
8. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.
Saydam O; Shen Y; Würdinger T; Senol O; Boke E; James MF; Tannous BA; Stemmer-Rachamimov AO; Yi M; Stephens RM; Fraefel C; Gusella JF; Krichevsky AM; Breakefield XO
Mol Cell Biol; 2009 Nov; 29(21):5923-40. PubMed ID: 19703993
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathogenesis of meningiomas.
Perry A; Gutmann DH; Reifenberger G
J Neurooncol; 2004 Nov; 70(2):183-202. PubMed ID: 15674477
[TBL] [Abstract][Full Text] [Related]
10. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
Ludwig N; Kim YJ; Mueller SC; Backes C; Werner TV; Galata V; Sartorius E; Bohle RM; Keller A; Meese E
Neuro Oncol; 2015 Sep; 17(9):1250-60. PubMed ID: 25681310
[TBL] [Abstract][Full Text] [Related]
11. Histological classification and molecular genetics of meningiomas.
Riemenschneider MJ; Perry A; Reifenberger G
Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285
[TBL] [Abstract][Full Text] [Related]
12. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of beta-catenin/E-cadherin in meningiomas.
Brunner EC; Romeike BF; Jung M; Comtesse N; Meese E
Histopathology; 2006 Aug; 49(2):178-87. PubMed ID: 16879395
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations associated with progression and recurrence in meningiomas.
Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and management differences for grade II and III spinal meningiomas.
Krauss WE; Yolcu YU; Alvi MA; Moinuddin FM; Goyal A; Clarke MJ; Marsh WR; Bydon M
J Neurooncol; 2021 Jun; 153(2):313-320. PubMed ID: 33973145
[TBL] [Abstract][Full Text] [Related]
18. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
19. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
20. World Health Organization Grade III Meningiomas: A Retrospective Study at an Academic Medical Center.
Sá-Marta E; Alves JL; Rebelo O; Barbosa M
World Neurosurg; 2021 May; 149():e877-e893. PubMed ID: 33516862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
